Progress in Detection of EGFR Exon 20 Insertion Mutation and Targeted Therapies
in Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2023.102.06
- Author:
Yulu WANG
1
;
Tianqing CHU
2
Author Information
1. Department of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University,
Shanghai 200030, China.
2. Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University,
Shanghai 200030, China.
- Publication Type:Journal Article
- Keywords:
Detection method;
Epidermal growth factor receptor ex20ins mutation;
Lung neoplasms;
Target therapy
- MeSH:
United States;
Humans;
Carcinoma, Non-Small-Cell Lung;
Mutagenesis, Insertional;
Lung Neoplasms;
ErbB Receptors;
Exons
- From:
Chinese Journal of Lung Cancer
2023;26(2):135-147
- CountryChina
- Language:Chinese
-
Abstract:
Epidermal growth factor receptor exon 20 insertion (EGFR ex20ins) is one of the earliest driver gene activation mutations in non-small cell lung cancer (NSCLC). However, due to the unique structure of protein variation caused by this mutation, most patients with EGFR ex20ins mutation (except A763_Y764insFQEA) have poor response to the launched first/second/third generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). With the successive approval of new specific targeted drugs for EGFR ex20ins in Food and Drug Administration (FDA) and other national regulatory agencies, the development and clinical research of targeted drugs for EGFR ex20ins in China have also developed rapidly and Mobocertinib has been approved recently in China. It is worth noting that EGFR ex20ins is a variant type with strong molecular heterogeneity. How to detect it comprehensively and accurately in clinical practice, so as to enable more patients to benefit from targeted therapy, is a very important and urgent problem to be solved. This review introduces the molecular typing of EGFR ex20ins, then discusses the importance of EGFR ex20ins detection and the differences of various detection methods, and summarizes the research and development of new drugs progress of EGFR ex20ins, in order to optimize the diagnosis and treatment path of EGFR ex20ins patients by selecting accurate, rapid and appropriate detection methods, so as to improve the clinical benefits of the patients.
.
